Acne treatments have remained largely the same for the last 30 years. That is why Dermira is looking to bring a cure to market that addresses the oils behind acne. It could eradicate the problem for the millions of Americans who suffer from chronic and extreme acne. Dermira is a publicly-traded biopharmaceutical company that focuses on cures for chronic skin conditions. Lori Lyons-Williams is the Chief Commerical Officer, and she joins Cheddar to break down some of the major news from this last quarter. Dermira acquired a product that, if approved, will help cure eczema. The painful, itchy, red, rash has very few treatments and relief. Another big piece of news for Dermira was its announcement that the FDA accepted its application for the medicine Glycopyrroniumtosylate. This drug treats axillary hyperhidrosis, otherwise known as extreme sweating. If things continue as planned, the drug could be on the market by next summer.